Identification of levothyroxine antichagasic activity through computer-aided drug repurposing

The Scientific World Journal

Volumn 2014, Issue , 2014, Pages

  Bellera, Carolina L ^a   Balcazar, Darío E ^b   Alberca, Lucas ^a   Labriola, Carlos A ^b   Talevi, Alan ^a   Carrillo, Carolina ^b  

^a FACULTAD DE CIENCIAS EXACTAS   (Argentina)

^b Facultad de Ciencias Naturales e Instituto M Lillo   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

CRUZIPAIN; LEVOTHYROXINE; ANTIPROTOZOAL AGENT; CYSTEINE PROTEINASE; CYSTEINE PROTEINASE INHIBITOR; PROTOZOAL PROTEIN; THYROXINE;

ANTICHAGASIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; DATA BASE; DRUG ACTIVITY; DRUG APPROVAL; DRUG CONFORMATION; DRUG IDENTIFICATION; DRUG REPOSITIONING; ENZYME ACTIVE SITE; ENZYME INHIBITION; EPIMASTIGOTE; FOOD AND DRUG ADMINISTRATION; HORMONE SUBSTITUTION; HUMAN; HYPOTHYROIDISM; QUANTITATIVE STRUCTURE ACTIVITY RELATION; TRYPANOSOMA CRUZI; CHEMISTRY; DRUG DESIGN; DRUG EFFECT; ENZYMOLOGY; METABOLISM; PROTEIN BINDING;

ANTIPROTOZOAL AGENTS; CATALYTIC DOMAIN; CYSTEINE ENDOPEPTIDASES; CYSTEINE PROTEINASE INHIBITORS; DRUG DESIGN; PROTEIN BINDING; PROTOZOAN PROTEINS; THYROXINE; TRYPANOSOMA CRUZI;

EID: 84896874963     PISSN: None     EISSN: 1537744X     Source Type: Journal    
DOI: 10.1155/2014/279618     Document Type: Article

References (49)

1. Coura J. R., De Castro S. L., A critical review on chagas disease chemotherapy. Memorias do Instituto Oswaldo Cruz 2002 97 1 3 24 2-s2.0-0036359943
2. Moncayo Á., Silveira A. C., Current epidemiological trends for Chagas disease in Latin America and future challenges in epidemiology, surveillance and health policy. Memorias do Instituto Oswaldo Cruz 2009 104 supplement 1 17 30 2-s2.0-68949203215
3. World Health Organization,. Control of Chagas disease. Second report of the WHO Expert Committee, 2002
4. TDR, Special Programme for Research and Training in tropical diseases), World Health Organiza-tion. Research priorities for Chagas disease, human African trypanosomiasis and leishmaniasis, 2012
5. Urbina J. A., Docampo R., Specific chemotherapy of Chagas disease: controversies and advances. Trends in Parasitology 2003 19 11 495 501 2-s2.0-0142227145 10.1016/j.pt.2003.09.001
6. Murcia L., Carrilero B., Segovia M., Limitations of currently available Chagas disease chemotherapy. Revista Española De Quimioterapia 2012 25 1 1 3
7. Astelbauer F., Walochnik J., Antiprotozoal compounds: state of the art and new developments. International Journal of Antimicrobial Agents 2011 38 2 118 124 2-s2.0-79959738612 10.1016/j.ijantimicag.2011.03.004
8. Villalta F., Scharfstein J., Ashton A. W., Tyler K. M., Guan F., Mukherjee S., Lima M. F., Alvarez S., Weiss L. M., Huang H., MacHado F. S., Tanowitz H. B., Perspectives on the Trypanosoma cruzi-host cell receptor interactions. Parasitology Research 2009 104 6 1251 1260 2-s2.0-67349272266 10.1007/s00436-009-1383-3
9. Cuervo P., Domont G. B., De Jesus J. B., Proteomics of trypanosomatids of human medical importance. Journal of Proteomics 2010 73 5 845 867 2-s2.0-77249169142 10.1016/j.jprot.2009.12.012
10. Sánchez-Sancho F., Campillo N. E., Páez J. A., Chagas disease: progress and new perspectives. Current Medicinal Chemistry 2010 17 5 423 452 2-s2.0-77950649397 10.2174/092986710790226101
11. Duschak V. G., Couto A. S., An insight on targets and patented drugs for chemotherapy of chagas disease. Recent Patents on Anti-Infective Drug Discovery 2007 2 1 19 51 2-s2.0-34248375271 10.2174/157489107779561625
12. Duschak V. G., Couto A. S., Cruzipain, the major cysteine protease of Trypanosoma cruzi: a sulfated glycoprotein antigen as relevant candidate for vaccine development and drug target. A review. Current Medicinal Chemistry 2009 16 24 3174 3202 2-s2.0-70350726376 10.2174/092986709788802971
13. Rodrigues G. C., Aguiar A. P., da Silva Gonçalves Vianez J. L. Jr., Macrae A., de Melo A. C. N., Vermelho A. B., Peptidase inhibitors as a possible therapeutic strategy for chagas disease. Current Enzyme Inhibition 2010 6 4 183 194 2-s2.0-79954507305 10.2174/157340810794578506
14. Knox C., Law V., Jewison T., Liu P., Ly S., Frolkis A., Pon A., Banco K., Mak C., Neveu V., Djoumbou Y., Eisner R., Guo A. C., Wishart D. S., DrugBank 3.0: a comprehensive resource for 'Omics' research on drugs. Nucleic Acids Research 2011 39 1 D1035 D1041 2-s2.0-78651287426 10.1093/nar/gkq1126
15. Wishart D. S., Knox C., Guo A. C., Shrivastava S., Hassanali M., Stothard P., Chang Z., Woolsey J., DrugBank: a comprehensive resource for in silico drug discovery and exploration. Nucleic Acids Research 2006 34 D668 672 2-s2.0-33644876210
16. Gan F., Cao B., Wu D., Chen Z., Hou T., Mao X., Exploring old drugs for the treatment of hematological malignancies. Current Medicinal Chemistry 2011 18 10 1509 1514 2-s2.0-79955033762 10.2174/092986711795328427
17. Talevi A., Castro E. A., Bruno-Blanch L. E., Castro E. A., Haghi A. K., Virtual screening: an emergent, key methodology for drug development in an emergent continent-a bridge towards patentability. Advances Methods and Applications in Chmoinformatics: Research Progress and New Applications 2011 1st Hershey, Pa, USA IGI Global 229 246
18. Deftereos S. N., Andronis C., Friedla E. J., Persidis A., Persidis A., Drug repurposing and adverse event prediction using high-throughput literature analysis. Wiley Interdisciplinary Reviews: Systems Biology and Medicine 2011 3 3 323 334 2-s2.0-79960304811 10.1002/wsbm.147
19. Lussier Y. A., Chen J. L., The emergence of genome-based drug repositioning. Science Translational Medicine 2011 3 96 96ps35
20. Ekins S., Williams A. J., Krasowski M. D., Freundlich J. S., In silico repositioning of approved drugs for rare and neglected diseases. Drug Discovery Today 2011 16 7-8 298 310 2-s2.0-79953695916 10.1016/j.drudis.2011.02.016
21. Sardana D., Zhu C., Zhang M., Gudivada R. C., Yang L., Jegga A. G., Drug repositioning for orphan diseases. Briefings in Bioinformatics 2011 12 4 346 356 2-s2.0-79960775459 10.1093/bib/bbr021
22. Pollastri M. P., Campbell R. K., Target repurposing for neglected diseases. Future Medicinal Chemistry 2011 3 10 1307 1315 2-s2.0-82555161767
23. dos Santos Filho J. M., Leite A. C. L., Oliveira B. G. D., Moreira D. R. M., Lima M. S., Soares M. B. P., Leite L. F. C. C., Design, synthesis and cruzain docking of 3-(4-substituted-aryl)-1,2,4-oxadiazole-N-acylhydrazones as anti-Trypanosoma cruzi agents. Bioorganic and Medicinal Chemistry 2009 17 18 6682 6691 2-s2.0-69349097629 10.1016/j.bmc.2009.07.068
24. Hernandes M. Z., Rabello M. M., Leite A. C. L., Cardoso M. V. O., Moreira D. R. M., Brondani D. J., Simone C. A., Reis L. C., Souza M. A., Pereira V. R. A., Ferreira R. S., McKerrow J. H., Studies toward the structural optimization of novel thiazolylhydrazone- based potent antitrypanosomal agents. Bioorganic and Medicinal Chemistry 2010 18 22 7826 7835 2-s2.0-78449262280 10.1016/j.bmc.2010.09.056
25. Rodrigues C. R., Flaherty T. M., Springer C., McKerrow J. H., Cohen F. E., CoMFA and HQSAR of acylhydrazide cruzain inhibitors. Bioorganic and Medicinal Chemistry Letters 2002 12 11 1537 1541 2-s2.0-0037013438 10.1016/S0960-894X(02)00189-0
26. Huang L., Brinen L. S., Ellman J. A., Crystal structures of reversible ketone-Based inhibitors of the cysteine protease cruzain. Bioorganic and Medicinal Chemistry 2003 11 1 21 29 2-s2.0-6444244485 10.1016/S0968-0896(02) 00427-3
27. Choe Y., Brinen L. S., Price M. S., Engel J. C., Lange M., Grisostomi C., Weston S. G., Pallai P. V., Cheng H., Hardy L. W., Hartsough D. S., McMakin M., Tilton R. F., Baldino C. M., Craik C. S., Development of α -keto-based inhibitors of cruzain, a cysteine protease implicated in Chagas disease. Bioorganic and Medicinal Chemistry 2005 13 6 2141 2156 2-s2.0-13844308925 10.1016/j.bmc.2004.12.053
28. Beaulieu C., Isabel E., Fortier A., Massé F., Mellon C., Méthot N., Ndao M., Nicoll-Griffith D., Lee D., Park H., Black W. C., Identification of potent and reversible cruzipain inhibitors for the treatment of Chagas disease. Bioorganic and Medicinal Chemistry Letters 2010 20 24 7444 7449 2-s2.0-78449283849 10.1016/j.bmcl.2010.10.015
29. Du X., Hansell E., Engel J. C., Caffrey C. R., Cohen F. E., McKerrow J. H., Aryl ureas represent a new class of anti-trypanosomal agents. Chemistry and Biology 2000 7 9 733 742 2-s2.0-0033830860 10.1016/S1074-5521(00)00018-1
30. Brak K., Doyle P. S., McKerrow J. H., Ellman J. A., Identification of a new class of nonpeptidic inhibitors of cruzain. Journal of the American Chemical Society 2008 130 20 6404 6410 2-s2.0-43949095150 10.1021/ja710254m
31. Mott B. T., Ferreira R. S., Simeonov A., Jadhav A., Ang K. K.-H., Leister W., Shen M., Silveira J. T., Doyle P. S., Arkin M. R., McKerrow J. H., Inglese J., Austin C. P., Thomas C. J., Shoichet B. K., Maloney D. J., Identification and optimization of inhibitors of trypanosomal cysteine proteases: cruzain, rhodesain, and TbCatB. Journal of Medicinal Chemistry 2010 53 1 52 60 2-s2.0-74849121149 10.1021/jm901069a
32. Ferreira R. S., Simeonov A., Jadhav A., Eidam O., Mott B. T., Keiser M. J., McKerrow J. H., Maloney D. J., Irwin J. J., Shoichet B. K., Complementarity between a docking and a high-throughput screen in discovering new cruzain inhibitors. Journal of Medicinal Chemistry 2010 53 13 4891 4905 2-s2.0-77954334175 10.1021/jm100488w
33. Ang K. K. H., Ratnam J., Gut J., Legac J., Hansell E., Mackey Z. B., Skrzypczynska K. M., Debnath A., Engel J. C., Rosenthal P. J., McKerrow J. H., Arkin M. R., Renslo A. R., Mining a cathepsin inhibitor library for new antiparasitic drug leads. PLoS Neglected Tropical Diseases 2011 5 5 2-s2.0-79957989066 10.1371/journal.pntd.0001023 e1023
34. Scheidt K. A., Roush W. R., McKerrow J. H., Selzer P. M., Hansell E., Rosenthal P. J., Structure-based design, synthesis and evaluation of conformationally constrained cysteine protease inhibitors. Bioorganic and Medicinal Chemistry 1998 6 12 2477 2494 2-s2.0-0032436499 10.1016/S0968-0896(98) 80022-9
35. Golbraikh A., Shen M., Xiao Z., Xiao Y.-D., Lee K.-H., Tropsha A., Rational selection of training and test sets for the development of validated QSAR models. Journal of Computer-Aided Molecular Design 2003 17 2-4 241 253 2-s2.0-0042355453 10.1023/A:1025386326946
36. Golbraikh A., Tropsha A., Predictive QSAR modeling based on diversity sampling of experimental datasets for the training and test set selection. Molecular Diversity 2000 5 4 231 243 2-s2.0-0036933967 10.1023/A:1021372108686
37. Kawabata T., Build-up algorithm for atomic correspondence between chemical structures. Journal of Chemical Information and Modeling 2011 51 8 1775 1782 2-s2.0-80051966794 10.1021/ci2001023
38. Hariharan R., Janakiraman A., Nilakantan R., Singh B., Varghese S., Landrum G., Schuffenhauer A., MultiMCS: a fast algorithm for the maximum common substructure problem on multiple molecules. Journal of Chemical Information and Modeling 2011 51 4 788 806 2-s2.0-79955388687 10.1021/ci100297y
39. Everitt B. S., Landau S., Leese M., Stahl D., Balding D. J., Cressie N. A. C., Fitzmaurice G. M., Goldstein H., Molenberghs G., Scott D. W., Smith A. F. M., Tsay R. S., Weisberg S., Optimization clustering techniques. Cluster Analysis 2011 5th Chichester, UK John Wiley & Sons 111 142
40. Talevi A., Bellera C. L., Di Ianni M. E., Duchowicz P. R., Bruno-Blanch L. E., Castro E. A., An integrated drug development approach applying topological descriptors. Computers Aid Drug Design and Discovery 2012 8 172 181
41. Yasri A., Hartsough D., Toward an optimal procedure for variable selection and QSAR model building. Journal of Chemical Information and Computer Sciences 2001 41 3-6 1218 1227 2-s2.0-0035438386
42. Truchon J.-F., Bayly C. I., Evaluating virtual screening methods: good and bad metrics for the "early recognition" problem. Journal of Chemical Information and Modeling 2007 47 2 488 508 2-s2.0-34247272948 10.1021/ci600426e
43. Gálvez J., García-Domenech R., De Gregorio Alapont C., De Julián-Ortiz J. V., Popa L., Pharmacological distribution diagrams: a tool for de novo drug design. Journal of Molecular Graphics 1997 14 5 272 276 2-s2.0-0030265277 10.1016/S0263-7855(96)00081-1
44. Triballeau N., Acher F., Brabet I., Pin J.-P., Bertrand H.-O., Virtual screening workflow development guided by the "receiver operating characteristic" curve approach. Application to high-throughput docking on metabotropic glutamate receptor subtype 4. Journal of Medicinal Chemistry 2005 48 7 2534 2547 2-s2.0-17144385534 10.1021/jm049092j
45. Labriola C., Sousa M., Cazzulo J. J., Purification of the major cysteine proteinase (cruzipain) from Trypanosoma cruzi by affinity chromatography. Biological Research 1993 26 1-2 101 107 2-s2.0-0027818526
46. Cazzulo J. J., Cazzulo Franke M. C., Martinez J., Franke De Cazzulo B. M., Some kinetic properties of a cysteine proteinase (cruzipain) from Trypanosoma cruzi. Biochimica et Biophysica Acta 1990 1037 2 186 191 2-s2.0-0025023473 10.1016/0167-4838(90)90166-D
47. Cazzulo J. J., Franke de Cazzulo B. M., Engel J. C., Cannata J. J. B., End products and enzyme levels of aerobic glucose fermentation in trypanosomatids. Molecular and Biochemical Parasitology 1985 16 3 329 343 2-s2.0-0022194396
48. Randić M., Similarity based on extended basis descriptors. Journal of Chemical Information and Computer Science 1992 32 686 692 2-s2.0-33751392179
49. Jadhav A., Ferreira R. S., Klumpp C., Mott B. T., Austin C. P., Inglese J., Thomas C. J., Maloney D. J., Shoichet B. K., Simeonov A., Quantitative analyses of aggregation, autofluorescence, and reactivity artifacts in a screen for inhibitors of a thiol protease. Journal of Medicinal Chemistry 2010 53 1 37 51 2-s2.0-74849118854 10.1021/jm901070c